Contact
GBG Forschungs GmbH
Martin-Behaim-Straße 12
63263 Neu-Isenburg
Germany
Phone.: +49610274800
Fax: +4961027480440
E-Mail: Infgbgd
Contact form
News
12.12.2019 SABCS 2019: Effects of capecitabine in neo-/adjuvant chemotherapy
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
Mehr ...06.12.2019 GBG presentations at SABCS
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
Mehr ...29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
Mehr ...08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
Mehr ...21.10.2019 ESMO 2019 Congress: Merit Award
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
Mehr ...
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440